---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-025588"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:01:39.339091+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Lantheus acquires Cerveau Technologies, adding Alzheimer's Tau PET imaging agent MK-6240

## Summary
- Acquired Cerveau Technologies, gaining MK-6240, an F18-labeled PET imaging agent targeting Tau tangles in Alzheimer's disease.
- MK-6240 is currently used in over 60 academic and industry clinical trials by more than 16 pharmaceutical companies.
- Terms include upfront payment plus development and commercial milestone payments, with double-digit royalties on research revenue and commercial sales.
- Transaction structured as a stock purchase; seller to provide transition and clinical development services post-closing.
- Lantheus expects to expand its radiopharmaceutical diagnostic imaging pipeline into Alzheimer's disease.

## SEC filing metadata
- accession: 0001193125-23-025588
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312523025588/0001193125-23-025588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312523025588/d462129d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-025588
- JSON: https://secwatch.observer/filing/0001193125-23-025588.json
- Plain text: https://secwatch.observer/filing/0001193125-23-025588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.